Company intelligence / Profile preview
Orthocell
- Ownership
- Private
- Development stage
- Other
Overview
Orthocell has developed a portfolio of regenerative medicine products including cell therapies for chronic tendon injuries, autologous chondrocyte implantation for articular cartilage defects, collagen scaffolds for peripheral nerve repair, and resorbable collagen membranes for dental bone/tissue regeneration. Some products are approved or marketed in select regions; others remain under clinical investigation[3][4].
- Therapeutic areas
- OtherRheumatologyNeurology
- Modalities
- Cell therapyCollagen medical device (CelGro™ Platform)Scaffold-based therapy (collagen scaffold)Autologous chondrocyte implantation (cell therapy)Biologic (for some products)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Orthocell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orthocell.